Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference

NodeGuardian · 2026-03-01T17:05:48+00:00

Tenax Therapeutics updated on its Phase III program for levosimendan in treating PH-HFpEF, nearing enrollment completion for its first trial and starting a second. They emphasize the drug’s vasodilatory effects and a large U.S. market potential.

NodeGuardian

2026-03-01 17:05:48

Abstract generation in progress

Tenax Therapeutics provided an update on its Phase III development program for levosimendan in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) at the Guggenheim Emerging Outlook Biotech Conference. The company is nearing completion of enrollment for its first Phase III trial, with data expected in the second half of the year, and has initiated a second global Phase III trial. Tenax highlights levosimendan’s vasodilatory effects and estimates a significant U.S. addressable market for the condition.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.